Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
signs and symptoms pathological conditions | D013568 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VESICARE | Astellas Pharma | N-021518 RX | 2004-11-19 | 2 products, RLD, RS |
VESICARE LS | Astellas Pharma | N-209529 RX | 2020-05-26 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
solifenacin | ANDA | 2022-11-12 |
solifenacin succinate | ANDA | 2024-11-27 |
solifenacin succinate solifenacin succinate | ANDA | 2021-11-22 |
solifenacine succinate | ANDA | 2022-12-05 |
vesicare | New Drug Application | 2022-10-31 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
overactive urinary bladder | EFO_1000781 | D053201 | N32.81 |
urge urinary incontinence | EFO_0006865 | D053202 | N39.41 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Solifenacin Succinate, Vesicare Ls, Astellas | |||
9918970 | 2031-05-18 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | 1 | — | — | 1 |
Urinary incontinence | D014549 | — | R32 | — | — | 1 | — | — | 1 |
Enuresis | D004775 | — | R32 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 2 | — | — | — | 2 |
Dementia | D003704 | EFO_0003862 | F03 | — | 2 | — | — | — | 2 |
Drug common name | Solifenacin |
INN | solifenacin |
Description | Solifenacin is a member of isoquinolines. |
Classification | Small molecule |
Drug class | muscarinic receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1 |
PDB | — |
CAS-ID | 242478-37-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1734 |
ChEBI ID | — |
PubChem CID | 154059 |
DrugBank | DB01591 |
UNII ID | A8910SQJ1U (ChemIDplus, GSRS) |